



Published in final edited form as:

*J Sleep Disord Ther.* ; 3(2): 126–. doi:10.4172/2167-0277.1000e126.

## Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS)

Kenneth Blum, PhD, DHL<sup>1,4,5,6,7,\*</sup>, Marlene Oscar-Berman, PhD<sup>2</sup>, Rajendra D Badgaiyan, MD<sup>3</sup>, Khurshid A. Khurshid, MD<sup>1</sup>, and Mark S. Gold, MD<sup>1</sup>

<sup>1</sup>Department of Psychiatry, & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, USA

<sup>2</sup>Department of Psychiatry and Anatomy & Neurobiology, Boston University School of Medicine and Boston VA Healthcare System, Boston, Massachusetts, USA

<sup>3</sup>Department of Neuroimaging and Psychiatry, University of Buffalo College of Medicine, Buffalo, New York., USA

<sup>4</sup>Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach, California, USA

<sup>5</sup>Department of Nutrigenomics, IGENE, LLC, Austin, Texas, USA

<sup>6</sup>Dominion Diagnostics, LLC ., North Kingstown, Rhode Island, USA

<sup>7</sup>Department of Clinical Neurology, PATH Foundation NY., USA

### Abstract

It is well-known that sleep has a vital function especially as it relates to prevention of substance-related disorders as discussed in the DSM-V. We are cognizant that certain dopaminergic gene polymorphisms have been associated with various sleep disorders. The importance of “*normal dopamine homeostasis*” is tantamount for quality of life especially for the recovering addict. Since it is now know that sleep per se has been linked with metabolic clearance of neurotoxins in the brain, it is parsonomiuos to encourage continued research in sleep science, which should ultimately result in attenuation of sleep deprivation especially associated with substance related disorders.

### Keywords

sleep; dopaminergic system; neurogenetics; metabolic clearance of neurotoxins; Reward Deficiency Syndrome (RDS)

---

\*Corresponding author: Kenneth Blum, PhD, Department of Psychiatry, University of Florida, College of Medicine, Gainesville, Florida, USA. Tel. 619-890-2167; drd2gene@gmail.com.

#### Conflict of Interest:

Kenneth Blum holds US and Foreign patents on a nutraceutical complex and nutrigenomics. He is the owner of IGENE LLC. There are no other conflicts.

## Introduction

A sleep disorder, or somniphobia, is a medical disorder of the sleep patterns of a person or animal. Accordingly, some sleep disorders are serious enough to interfere with normal physical, mental and emotional functioning. Disruptions in sleep can be caused by a variety of issues, from teeth grinding bruxism to night terrors. Importantly, when a person suffers from difficulty falling asleep and staying asleep with no obvious cause, it is referred to as insomnia.<sup>1</sup> Dyssomnia refers to a group of sleep disorders with the symptoms of trouble falling asleep or maintaining sleep, which may cause an elevated sense of sleepiness during the day. Furthermore, Insomnia is characterized by an extended period of symptoms including trouble with retaining sleep, fatigue, decreased attentiveness, and dysphoria.

Clinicians agree that to diagnose insomnia, these symptoms must persist for a minimum of 4 weeks. The DSM-V categorizes insomnias into primary insomnia, insomnia associated with medical or mental diseases, and insomnia associated with the consumption or abuse of substances. Insomnia is also linked to negative health consequences such as anxiety and depression<sup>2</sup>.

It is well established that **virtually all substance related disorders (SRD) and psychiatric disturbances are associated with sleep disruption and psychiatric disorders are the most common cause of insomnia**<sup>3</sup>. Alcohol dependence leads to sleep disturbances that persist in many cases for months even after abstinence and recovery.<sup>4</sup> In fact, it has been noted that insomnia is a risk factor for depression, anxiety and SRD.<sup>5</sup>

There is significant evidence that sleep disorders such as **Sleep Disordered Breathing (SDR)**, Restless Leg Syndrome (RLS) and sleep-movement disorders are unrecognized in both adults and children with psychiatric disorders including SRD and even alcohol spectrum disorder.<sup>6</sup> Moreover, insomnia and certain types of EEG sleep patterns, such as reduced REM latency or increased REM sleep, have been relapse or recurrence of depression and alcoholism.<sup>7,8</sup> Across the number of Reward Deficiency Syndrome (RDS) subsets, for example, **Posttraumatic Stress Disorder (PTSD) has been associated with nightmares (e.g REM and NREM dream disturbances, movement disorders) and insomnia.**<sup>9</sup>

In terms of psychoactive drug abuse, specific effects on sleep have been observed and reported in the literature. For example, **heroin addicts often report sleep disturbances, notably insomnia, as precipitating causes of relapse.**<sup>10</sup> Methadone maintenance have resulted in SDB<sup>11</sup>, chronic cocaine addicts have lower sleep efficiency and significant sleep onset delay,<sup>12</sup> followed by hypersomnia upon withdrawal or abstinence.<sup>13</sup> Users of GHB (gamma-hydroxybutyrate) experience constant waking and must take more to reinstate sleep.<sup>14</sup> It is noteworthy that **cytokines regulate sleep and a number of CNS functions including opioid systems and even food consumption.**<sup>15</sup>

Interestingly, neuroimaging studies have revealed neuro-anatomic correlates of sleep disturbance in depression and schizophrenia, showing that schizophrenics present slow wave deficits and frontal cortical volume loss;<sup>16</sup> depressed patients show higher absolute cerebral glucose metabolic rate than healthy subjects, and blunted activation of limbic structures (amygdala, anterior cingulate) during REM sleep compared to wakefulness.<sup>17</sup> Certainly, we

must be cognizant that many drugs can damage brain areas and neural pathways in sleep maintenance. One example is MDMA (“ecstasy”), which has been shown to induce a reduction in serotonin axons and axon terminals.<sup>18</sup> One other example of drug induced brain damage, is that cocaine, causes severe depletion of dopaminergic neural pathways especially in low serotonin function.<sup>19</sup>

Importantly, young adults diagnosed with attention-deficit-hyperactivity disorder (ADHD), a known subset of RDS, show evidence for sleep-disorders<sup>20</sup> and these patients should be monitored for delayed sleep phase disorder.<sup>21</sup> Understanding the neural correlates of sleep function especially trait based neurogenetic dopaminergic polymorphic antecedents and state epigenetic induced dysfunction of sleep is tantamount to providing informative treatment strategies.

## Dopaminergic Neurogenetics and Sleep Disorders

In this commentary we are compelled to briefly describe the potential neurogenetic and epigenetic effects on sleep. It is well-known that healthy homozygous 10-repeat (10R/10R) allele carriers of this genetic variant have reduced striatal dopamine transporter [DAT] protein expression when compared with 9-repeat (9R) allele carriers. Holst *et al.*<sup>22</sup> found that slow-wave sleep, electroencephalographic slow-wave activity (0.5-4.5 Hz), and number of low-frequency (0.5-2.0 Hz) oscillations in non-rapid-eye-movement sleep, was significantly larger in the 10R/10R genotype than in the 9R allele carriers of DAT1. The results would suggest that dopamine transporter plays a role in regulating neurophysiological markers of sleep-homeostasis in humans. Moreover, Landolt *et al.*<sup>23</sup> pointed out that the contribution of slow brain oscillations including delta, theta, alpha, and sigma frequencies (0.5-16 Hz) to the sleep electroencephalography (EEG) is regulated by circadian and homeostatic influences, and reflects functional aspects of wakefulness and sleep. Accumulating evidence demonstrates that individual sleep EEG patterns in non-rapid-eye-movement (NREM) sleep and rapid-eye-movement (REM) sleep are heritable traits. More specifically, multiple recordings in the same individuals, as well as studies in monozygotic and dizygotic twins suggest that a very high percentage of the robust inter-individual variation and the high intraindividual stability of sleep EEG profiles can be explained by genetic factors (> 90% in distinct frequency bands). However, there is no association found within intron 8 of the DAT1 gene and sleep architecture measured by SPECT<sup>24</sup>.

It is well known that a functional polymorphism in the gene encoding catechol-O-methyltransferase (COMT), an enzyme involved in cortical dopamine metabolism, causes a common substitution of methionine (Met) for valine (Val) at codon 158 of COMT protein. Resultant Val allele homozygotes exhibit higher COMT activity and lower dopaminergic function in prefrontal cortex than Met/Met homozygotes. Specifically, Catechol-O-methyltransferase (COMT) inactivates norepinephrine and dopamine via methyl conjugation, and a G-A transition in the COMT gene (rs4680) influences the enzyme activity. Bodenmann *et al.*<sup>25</sup> reported that the Val158Met polymorphism predicts stable and frequency-specific, inter-individual variation in brain alpha oscillations. Alpha peak frequency in wakefulness was 1.4 Hz slower in Val/Val genotype than in Met/Met genotype.

In addition, Val/Val allele carriers exhibited less 11-13 Hz activity than Met/Met homozygotes in wakefulness, rapid-eye-movement (REM) sleep, and non-REM sleep. Polymorphisms of the COMT gene has been also shown to influence the anti-depressant effects certain drugs when utilized for bipolar depression and associated sleep problems<sup>26</sup>.

Other work related to the relationships among the variable number of tandem repeats in the monoamine oxidase-A linked polymorphic region allelic variation (MAOA-uVNTR) and the symptoms of depression and sleep quality has been executed by Brummett *et al.*<sup>27</sup> The MAOA gene, plays a role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, and contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency. Interesting, Brummett *et al.*<sup>27</sup> found that MAOA-uVNTR alleles associated with less transcriptional activity presented with increased symptoms of depression ( $p < .04$ ; Cohen's  $d = 0.52$ ) and poorer sleep quality ( $p < .04$ ; Cohen's  $d = 0.31$ ). Therefore, these results suggest that patients with less active MAOA-uVNTR alleles may be at increased risk for depressive symptoms and poor sleep. Along these lines studies continue on evaluating reward gene polymorphisms and long and short sleep animal models<sup>28</sup>; circadian rhythm<sup>29</sup> as well as innate physical activity<sup>30</sup>.

## Future Perspectives and Encouraged Research

The role of sleep in complex disorders like RDS is extremely important especially in terms of relapse prevention. Most recently evidence is accumulating showing that sleep has an important function in ensuring metabolic homeostasis. In mice, natural sleep is associated with a 60% increase in interstitial space and as such there is an increase in convective exchange of cerebrospinal fluid with interstitial fluid. This process results in an increased rate of  $\beta$ -amyloid clearance during sleep. According to Xie *et al.*<sup>31</sup> sleep drives metabolic brain clearance of potentially neurotoxic waste products. We are proposing that sleep may also clear foreign drug like compounds such as opioids as an example.

Understanding the long-term problem of sleep even in abstinent opiate abusers, based on this new knowledge we encourage our scientific peers to continue their research in developing tools that will enhance sleep in these patients a vital part of recovery.

## Acknowledgements

The authors appreciate the expert edits by Margaret A. Madigan, RN. The writing of this paper was supported in part by funds from the National Institutes of Health, NIAA (R01-AA07112 and K05-AA0219 and the Medical Research Service of the US Department of Veterans Affairs (MOB). RDB is partially funded by NINDS grant R01NS073884 and the VA Merit Review grants CX000479 and CX000780. The writing of this paper was funded in-part by a grant awarded to Kenneth Blum & Eric R. Braverman from Life Extension Foundation, Ft. Lauderdale, Florida to PATH Foundation NY.

## References

1. Stuart, C. Essentials of neuropsychiatry and clinical neurosciences. 4 ed.. Yudofsky; Hales, Robert E., editors. American Psychiatric Publishing; Arlington, Virginia, USA:
2. Voderholzer, Ulrich; Guilleminault, Christian. "Sleep disorders". *Neurobiology of Psychiatric Disorders. Handbook of Clinical Neurology.* 2012; 106:527–40. [PubMed: 22608642]

3. Park SC, Kim JM, Jun TY, Lee MS, Kim JB, Jeong SH, Park YC. Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study. *Psychiatry Investig.* 2013; 10(4):373–81.
4. Zhabenko O, Krentzman AR, Robinson EA, Brower KJ. A longitudinal study of drinking and depression as predictors of insomnia in alcohol-dependent individuals. *Subst Use Misuse.* 2013; 48(7):495–505. [PubMed: 23566203]
5. Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. *Sleep.* 2007; 30(7):873–80. [PubMed: 17682658]
6. Ipsiroglu OS, McKellin WH, Carey N, Loock C. “They silently live in terror...” why sleep problems and night-time related quality-of-life are missed in children with a fetal alcohol spectrum disorder. *Soc Sci Med.* 2013; 79:76–83. [PubMed: 23305724]
7. Clark CP, Gillin JC, Golshan S, Demodena A, Smith TL, Danowski S, Irwin M, Schuckit M. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression. *Biol Psychiatry.* 1998; 43(8):601–607. [PubMed: 9564445]
8. Brower KJ. Insomnia, alcoholism and relapse. *Sleep Med Rev.* 2003; 7(6):523–39. [PubMed: 15018094]
9. Manni R, Ratti PL, Terzaghi M. Secondary “incidental” REM sleep behavior disorder: do we ever think of it? *Sleep Med.* 2011; 12(Suppl 2):S50–3. [PubMed: 22136900]
10. Nettleton S, Neale J, Pickering L. Techniques and transitions: a sociological analysis of sleeping practices amongst recovering heroin users. *Soc Sci Med.* 2011; 72(8):1367–73. [PubMed: 21458902]
11. Pud D, Zlotnick C, Lawental E. Pain depression and sleep disorders among methadone maintenance treatment patients. *Addict Behav.* 2012; 37(11):1205–10. [PubMed: 22742985]
12. Matuskey D, Pittman B, Forselius E, Malison RT, Morgan PT. A multistudy analysis of the effects of early cocaine abstinence on sleep. *Drug Alcohol Depend.* 2011; 115(1-2):62–6. [PubMed: 21144676]
13. Morgan PT, Malison RT. Cocaine and sleep: early abstinence. *Scientific World Journal.* 2007; 7:223–30. [PubMed: 17982597]
14. Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. *Sleep Med Rev.* 2012; 16(5):431–43. [PubMed: 22055895]
15. Reyes-Vázquez C, Prieto-Gómez B, Dafny N. Interferon modulates central nervous system function. *Brain Res.* Mar 9. 2012 2012 1442:76–89. [PubMed: 22322149]
16. Lauer CJ, Krieg JC. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression. *Biol Psychiatry.* 1998; 44(2):121–128. [PubMed: 9646894]
17. Wu JC, Gillin JC, Buchsbaum MS, Schachat C, Darnall LA, Keator DB, Fallon JH, Bunney WE. Sleep deprivation PET correlations of Hamilton symptom improvement ratings with changes in relative glucose metabolism in patients with depression. *J Affect Disord.* 2008; 107(1-3):181–6. [PubMed: 18031825]
18. Schouw ML, Gevers S, Caan MW, Majoie CB, Booij J, Nederveen AJ, Reneman L. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI. *Eur Neuropsychopharmacol.* 2012; 22(8):537–45. [PubMed: 22209360]
19. Cox SM, Benkelfat C, Dagher A, Delaney JS, Durand F, Kolivakis T, Casey KF, Leyton M. Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [<sup>11</sup>C]raclopride study in humans. *Br J Psychiatry.* 2011; 199(5):391–397. [PubMed: 21543823]
20. Hvolby A, Jørgensen JI, Bilenberg N. Sleeping disorders can imitate attention deficit/hyperactivity disorder. *Ugeskr Laeger.* 2006; 167(41):3893–3894. [PubMed: 16221433]
21. Khurshid KA, Khan AA. Delayed sleep phase disorder and attention deficit and hyperactivity symptoms in a teenager. *Atten Defic Hyperact Disord.* Dec; 2009 2009 1(2):211–213. [PubMed: 21432583]
22. Holst SC, Bersagliere A, Bachmann V, Berger W, Achermann P, Landolt HP. Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans. *J Neurosci.* 2014; 34(2):566–573. [PubMed: 24403155]

23. Landolt HP. Genetic determination of sleep EEG profiles in healthy humans. *Prog Brain Res.* 2011; 193:51–61. [PubMed: 21854955]
24. Guindalini C, Martins RC, Andersen ML, Tufik S. Influence of genotype on dopamine transporter availability in human striatum and sleep architecture. *Psychiatry Res.* 2010; 179(2):238–40. [PubMed: 20493539]
25. Bodenmann S, Rusterholz T, Dürr R, Stoll C, Bachmann V, Geissler E, Jaggi-Schwarz K, Landolt HP. The functional Val158Met polymorphism of COMT predicts inter-individual differences in brain alpha oscillations in young men. *J Neurosci.* 2009; 29(35):10855–10862. [PubMed: 19726643]
26. Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Dallaspezia S, Gavinelli C, Locatelli C, Lorenzi C, Pirovano A, Radaelli D, Smeraldi E, Colombo C. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism. *J Affect Disord.* 2010; 121(1-2):68–72. [PubMed: 19520435]
27. Brummett BH, Krystal AD, Siegler IC, Kuhn C, Surwit RS, Züchner S, Ashley-Koch A, Barefoot JC, Williams RB. Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality. *Psychosom Med.* 2007; 69(5):396–401. [PubMed: 17585061]
28. Darlington TM, Ehringer MA, Larson C, Phang TL, Radcliffe RA. Transcriptome analysis of Inbred Long Sleep and Inbred Short Sleep mice. *Genes Brain Behav.* 2013; 12(2):263–274. [PubMed: 23433184]
29. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. *CNS Drugs.* 2009; 23(Suppl 2):15–26. [PubMed: 19708722]
30. Yang HS, Shimomura K, Vitaterna MH, Turek FW. High-resolution mapping of a novel genetic locus regulating voluntary physical activity in mice. *Genes Brain Behav.* 2012; 11(1):113–124. [PubMed: 21978078]
31. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. *Science.* 2013; 342(6156):373–377. [PubMed: 24136970]